Canaccord Genuity Group Cuts Compass Pathways (NASDAQ:CMPS) Price Target to $18.00

Compass Pathways (NASDAQ:CMPS) had its price objective reduced by Canaccord Genuity Group from $20.00 to $18.00 in a report issued on Thursday morning,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

CMPS has been the topic of several other reports. Compass Point set a $15.00 price objective on Compass Pathways in a research note on Thursday, February 12th. Lifesci Capital raised shares of Compass Pathways to a “strong-buy” rating in a report on Thursday, February 12th. Royal Bank Of Canada raised their price target on shares of Compass Pathways from $21.00 to $22.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Pathways in a report on Wednesday, January 21st. Finally, Morgan Stanley lowered their price objective on shares of Compass Pathways from $18.00 to $16.00 and set an “overweight” rating for the company in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Compass Pathways presently has a consensus rating of “Moderate Buy” and an average target price of $21.63.

Compass Pathways Stock Down 4.8%

Shares of Compass Pathways stock opened at $5.37 on Thursday. The business has a 50-day moving average price of $6.66 and a 200 day moving average price of $6.30. Compass Pathways has a fifty-two week low of $2.25 and a fifty-two week high of $8.90. The firm has a market cap of $515.63 million, a P/E ratio of -1.74 and a beta of 1.90. The company has a quick ratio of 1.23, a current ratio of 0.77 and a debt-to-equity ratio of 0.55.

Compass Pathways (NASDAQ:CMPS) last issued its earnings results on Tuesday, March 24th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.59). On average, sell-side analysts forecast that Compass Pathways will post -2.33 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compass Pathways

Several large investors have recently added to or reduced their stakes in CMPS. Simplify Asset Management Inc. acquired a new position in shares of Compass Pathways during the third quarter valued at $1,662,000. Jefferies Financial Group Inc. acquired a new stake in shares of Compass Pathways in the 3rd quarter worth about $7,890,000. Propel Bio Management LLC acquired a new stake in shares of Compass Pathways in the 3rd quarter worth about $2,922,000. Blue Owl Capital Holdings LP lifted its position in Compass Pathways by 163.1% in the 3rd quarter. Blue Owl Capital Holdings LP now owns 604,914 shares of the company’s stock valued at $3,466,000 after purchasing an additional 375,000 shares during the last quarter. Finally, ARK Investment Management LLC boosted its stake in Compass Pathways by 28.6% during the 3rd quarter. ARK Investment Management LLC now owns 2,121,118 shares of the company’s stock valued at $12,154,000 after purchasing an additional 471,897 shares during the period. 46.19% of the stock is owned by institutional investors and hedge funds.

More Compass Pathways News

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating with a very high $70 price target, signaling a strong long‑term bullish case and large implied upside versus the current share price. (This supports investor optimism even as near‑term forecasts were adjusted.)
• Neutral Sentiment: Upcoming FDA review meeting for COMP360 is a potential binary catalyst — outcomes or guidance from that meeting could swing sentiment materially in either direction. Compass Pathways (CMPS): What will come out of FDA review meeting for depression drug candidate COMP360?
• Neutral Sentiment: Canaccord cut its price target from $20 to $18 but kept a “Buy” rating — a modest downgrade that still implies significant upside from current levels. Canaccord target cut report
• Negative Sentiment: HC Wainwright lowered its FY2026 EPS forecast to ($1.66) from ($1.36) and cut FY2027 to ($0.96) (previously $0.72), and issued lower quarterly EPS estimates across 2026–2027 — firms’ reduced profit outlook increases short‑term pressure on the share price.
• Negative Sentiment: Morgan Stanley trimmed its price target to $16, which reduces near‑term upside and may prompt short‑term selling. Morgan Stanley Lowers Compass Pathways (NASDAQ:CMPS) Price Target to $16.00
• Negative Sentiment: Recent earnings (reported 3/24) missed estimates (EPS -$1.00 vs. consensus -$0.41), reinforcing concerns on near‑term profitability and contributing to downward pressure on the stock.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.